Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Public ClinicalTrials.gov record NCT06040541. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors
Study identification
- NCT ID
- NCT06040541
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Enrollment
- 604 participants
Conditions and interventions
Conditions
Interventions
- RMC-6236 Drug
- RMC-9805 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 6, 2023
- Primary completion
- Apr 29, 2026
- Completion
- Apr 29, 2027
- Last update posted
- Aug 27, 2025
2023 – 2027
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Davis Comprehensive Cancer Center | Sacramento | California | 95817 | Recruiting |
| Smilow Cancer Hospital (Yale University) | New Haven | Connecticut | 06511 | Recruiting |
| Florida Cancer Specialists | Sarasota | Florida | 34232 | Recruiting |
| Lee Moffitt Cancer Center | Tampa | Florida | 33612 | Recruiting |
| Johns Hopkins University | Baltimore | Maryland | 21287 | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| NYU Langone | New York | New York | 10016 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| Duke Cancer Center | Durham | North Carolina | 27710 | Recruiting |
| Carolina BioOncology Institute | Huntersville | North Carolina | 28078 | Recruiting |
| The Christ Hospital | Cincinnati | Ohio | 45219 | Recruiting |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | Recruiting |
| Sarah Cannon Research Institute at Mary Crowley | Dallas | Texas | 75230 | Recruiting |
| University of Texas, MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| START | San Antonio | Texas | 78229 | Recruiting |
| NEXT Oncology Virginia | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06040541, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2025 · Synced Apr 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06040541 live on ClinicalTrials.gov.